Alternative Therapiestrategien chronischer Virushepatitiden

Zusammenfassung

Konventionelle Therapiestrategien bei chronischer Hepatitis B oder C zeigen nur mäßige Heilungserfolge und sind teilweise mit einer hohen Nebenwirkungsrate verbunden. Ferner stellen absolute und relative Kontraindikationen einer Interferontherapie Limitationen ihres Einsatzes dar.

In vorliegendem Artikel werden alternative Therapien bei chronischen Hepatitiden diskutiert. Ein anthroposophisches Therapiekonzept zeigt in ersten Studien Heilungsraten von bis zu 43 % bei chronischer Hepatitis C auf. Dabei werden das Anthroposophikum Mistelgesamtextrakt (Viscum album L.; Abnobaviscum®), die Phythopharmaka Solanum lycopersicum und Hepatodoron® neben ordnungstherapeutischen Elementen eingesetzt.

Das Phytopharmakon Glycyrrhizin/Sho-saiko-to aus der chinesischen und japanischen Naturheilkunde führt zu Transaminasenreduktion und weist einen mäßig positiven klinischen Langzeiteffekt bez. Zirrhosebildung und HCC-Entwicklung bei chronischer Hepatitis auf, ohne jedoch zu einer Ausheilung der Hepatitis zu führen. Andere Phytopharmaka wie Silymarin, Phyllantus spec., Colchicin sowie die Substanzen Ursodeoxycholsäure, Vitamin E und Misoprostol werden in ihrem Einfluss auf chronische Hepatitiden diskutiert.

Abstract

Conventional therapeutic strategies in chronic hepatitis B and C are only moderately successful. Furthermore, the therapy is often related to a high rate of side effects and the use of interferon is limited because of contraindications. In this article alternative therapeutic strategies are discussed. An anthroposophical therapeutic concept shows a sustained response rate of 43 % in preliminary studies. The concept includes herbal drugs (a mistletoe extract, phytotherapeutic Solanum lycopersicum and Hepatodoron®) and therapeutic elements of life style modification.

The traditional Japanese and Chinese medicine uses the herbal drug glycyrrhizin/Sho-saiko-to in therapy of hepatitis B and C. It leads to a reduction of transaminases and to a moderate positive long-term effect concerning cirrhosis and HCC in chronic hepatitis. However, a sustained response has not been described for glycyrrhizin. The relevance of other herbal drugs like silymarin, Phyllantus spec. and Colchicin and drugs like vitamin E, ursodeoxycholic acid or Misoprostol in chronic hepatitis are discussed.

Schlüsselwörter

Hepatitis - Komplimentärmedizin - anthroposophische Therapie - Phytotherapie - Mistel - Viscum album - Solanum lycopersicum - Hepatodoron - Glycyrrhizin - Sho-saiko-to - Silymarin - Phyllantus - Misoprostol - Ursodeoxycholsäure - Vitamin E

Key words

Hepatitis - Complementary Medicine - Anthroposophical Therapy - Phytotherapy - Mistletoe - Solanum lycopersicum - Hepatodoron - Glycyrrhizin - Sho-saiko-to - Silymarin - Phyllantus - Misoprostol - Ursodeoxycholic Acid - Vitamin E

Literatur

• 1 Malik A H, Lee W M. Chronic hepatitis B virus infection: treatment strattegies for the next millennium.  Ann Intern Med. 2000;  132 (9) 723-731
• 2 van Nunen A B, Janssen H L, Wolters L M, Niesters H G, de Man R A, Schalm S W. Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug?.  Antiviral Res. 2001;  52 (2) 139-146
• 3 Hagmeyer K O, Pan Y Y. Role of lamivudine in the treatment of chronic hepatitis B virus infection.  Ann Pharmacother. 1999;  33 (10) 1104-1112
• 4 Hoofnagle J H. Therapy of viral hepatitis.  Digestion. 1998;  59 (5) 563-578
• 5 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B.  Drugs. 1999;  58 (1) 101-141
• 6 Rizzetto M. Therapy of chronic viral hepatitis: a critical view.  Ital J Gastroenterol Hepatol. 1999;  31 (8) 781-793
• 7 Gordon S C. Treatment of viral hepatitis - 2001.  Ann Med. 2001;  33 (6) 385-390
• 8 Brown P J, Neuman M G. Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C.  Can J Clin Pharmacol. 2001;  8 (2) 67-71
• 9 Perry C M, Jarvis B. Peginterferon-alpha-2a (40kD): A Review of its Use in the Management of Chronic Hepatitis C.  Drugs. 2001;  61 (15) 2263-2288
• 10 Shiffman M L. Pegylated interferons: what role will they play in the treatment of chronic hepatitis c?.  Curr Gastroenterol Rep. 2001;  3 (1) 30-37
• 11 Manns M P, Cornberg M, Wedemeyer H. Current and future treatment of hepatitis C.  Indian J Gastroenterol. 2001;  20 (Suppl 1) C47-51
• 12 Berg P A, Stein G M. Einfluss einer Misteltherapie auf die Tumorabwehr - Eine kritische immunologische Analyse. Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V Die Mistel in der Tumortherapie Essen; KVC Verlag 2001: 95-107
• 13 Büssing A. Leben und sterben lassen - DNA-stabilisierende und zytotoxische Effekte von Viscum album L.-Extrakten. Scheer R, Becker H, Berg PA Grundlagen der Misteltherapie Stuttgart; Edition Forschung Hippokrates Verlag 1996: 191-196
• 14 Bantel H, Engels I H, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis.  Cancer Res. 1999;  59 (9) 2083-2090
• 15 Büssing A, Suzart K, Bergmann J, Pfuller U, Schietzel M, Schweizer K. Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins.  Cancer Lett. 1996;  99 (1) 59-72
• 16 Büssing A, Suzart K, Schweizer K. Differences in the apoptosis-inducing properties of Viscum album L. extracts.  Anticancer Drugs. 1997;  8 (Suppl 1) S9-14
• 17 Büssing A, Stein G M, Pfuller U, Schietzel M. Differential binding of toxic lectins from Viscum album L., ML I and ML III, to human lymphocytes.  Anticancer Res. 1999;  19 (6B) 5095-5099
• 18 Büssing A, Stein G M, Wagner M. et al . Accidental cell death and generation of reactive oxygen intermediates in human lymphocytes induced by thionins from Viscum album L.  Eur J Biochem. 1999;  262 (1) 79-87
• 19 Pape G R, Diepobler H M, Gerlach T J, Jung M C, Grüner N H, Schirren C A. Immunbiologie der Hepatitis-C- Virus-Infektion. Häussinger D, Niederau C Hepatitis C. Vol. 8 Berlin, Wien; Blackwell Wissenschafts-Verlag 2001: 50-63
• 20 Hayashi N. Apoptosis in liver disease.  Intern Med. 1998;  37 (2) 191-192
• 21 Lau J Y, Xie X, Lai M M, Wu P C. Apoptosis and viral hepatitis.  Semin Liver Dis. 1998;  18 (2) 169-176
• 22 Nasir A, Arora H S, Kaiser H E. Apoptosis and pathogenesis of viral hepatitis C - an update.  In Vivo. 2000;  14 (1) 297-300
• 23 Tai D I, Tsai S L. Apoptosis in viral hepatitis B and C.  Chang Gung Med J. 2001;  24 (5) 285-293
• 24 Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze M G. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.  J Virol. 1999;  73 (8) 6506-6516
• 25 Galle P R, Hofmann W J, Walczak H. et al . Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.  J Exp Med. 1995;  182 (5) 1223-1230
• 26 Matthes B, Mühlenfeld K, Langner A, Matthes H. Untersuchungen zur Toxikologie von Solanum lycopersicum.  Zeitschrift für Gastroenterologie. 1999;  9 898
• 27 Matthes B. Solanum lycopersicum als Heilpflanze.  Der Merkurstab. 1999;  52 (Sonderband) 57-67
• 28 Bantel H, Lugering A, Poremba C. et al . Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection.  Hepatology. 2001;  34 (4 Pt 1) 758-767
• 29 Matthes H, Grah C, Biesenthal S. Therapiestudie zur Hepatitis C mit Abnoba viscum und Solanum lycopersicum.  Der Merkurstab. 1997;  Sonderheft Juni 97 26
• 30 Matthes B, Grah C, Biesenthal S, Matthes H. Übersicht von Heilversuchen zur Therapie bei Hepatitis C mit Abnoba viscum und Solanum lycopersicum.  Zeitschrift für Gastroenterologie. 1998;  36 (8) 760
• 31 Huber R, Ludtke R, Klassen M, Muller-Buscher G, Wolff-Vorbeck G, Scheer R. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.  Eur J Med Res. 2001;  6 (9) 399-405
• 32 Tusenius K J, Spoek J M, Kramers C W. Iscador Qu for chronic hepatitis C: an exploratory study.  Complement Ther Med. 2001;  9 12-16 (1)
• 33 Matthes H. Aspekte zur Therapie der Hepatitis C.  Der Merkurstab. 1999;  52 (11) 25-41
• 34 Matthes H, Matthes B, Biesenthal S. Survey of unconventionally hepatitis C therapy with an aqueous mistletoe extract and lycopersicon esculentum.  Gastroenterology. 2000;  118 (5) A
• 35 Stein G M, Edlund U, Schaller G, Pfüller U, Büssing A, Schietzel M. Polysacharide und Viscotoxine - Immunologische Wirkung und Interaktionen. Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V Die Mistel in der Tumortherapie Essen; KVC Verlag 2001: 145-162
• 36 van Rossum T G, Vulto A G, de Man R A, Brouwer J T, Schalm S W. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C.  Aliment Pharmacol Ther. 1998;  12 (3) 199-205
• 37 Sato H, Goto W, Yamamura J. et al . Therapeutic basis of glycyrrhizin on chronic hepatitis B.  Antiviral Res. 1996;  30 (2-3) 171-177
• 38 Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.  Altern Med Rev. 1999;  4 (4) 220-238
• 39 van Rossum T G, Vulto A G, Hop W C, Schalm S W. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C.  Am J Gastroenterol. 2001;  96 (8) 2432-2437
• 40 Eisenburg J. Treatment of chronic hepatitis B. Part 2: Effect of glycyrrhizic acid on the course of illness.  Fortschr Med. 1992;  110 (21) 395-398
• 41 Arase Y, Ikeda K, Murashima N. et al . The long term efficacy of glycyrrhizin in chronic hepatitis C patients.  Cancer. 1997;  79 (8) 1494-1500
• 42 Park E J, Ko G, Kim J, Sohn D H. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction.  Biol Pharm Bull. 1997;  20 (4) 417-420
• 43 Yamashiki M, Nishimura A, Nobori T. et al . In vitro effects of sho-saiko-to on production of granulocyte colony-stimulating factor by mononuclear cells from patients with chronic hepatitis C.  Int J Immunopharmacol. 1997;  19 (7) 381-385
• 44 Yamashiki M, Nishimura A, Suzuki H, Sakaguchi S, Kosaka Y. Effects of the Japanese herbal medicine „Sho-saiko-to” (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C.  Hepatology. 1997;  25 (6) 1390-1397
• 45 Matsuo K, Takenaka K, Shimomura H. et al . Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma.  Leuk Lymphoma. 2001;  41 (1-2) 191-195
• 46 van Rossum T G, de Jong F H, Hop W C, Boomsma F, Schalm S W. „Pseudo-aldosteronism” induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients.  J Gastroenterol Hepatol. 2001;  16 (7) 789-795
• 47 Kageyama Y. A case of pseudoaldosteronism induced by glycyrrhizin.  Nippon Jinzo Gakkai Shi. 1992;  34 (1) 99-102
• 48 Kageyama Y, Suzuki H, Saruta T. Renin-dependency of glycyrrhizin- induced pseudoaldosteronism.  Endocrinol Jpn. 1991;  38 (1) 103-108
• 49 Shintani S, Murase H, Tsukagoshi H, Shiigai T. Glycyrrhizin (licorice)-induced hypokalemic myopathy. Report of 2 cases and review of the literature.  Eur Neurol. 1992;  32 (1) 44-51
• 50 Schuppan D, Strobel D, Hahn E G. Hepatic fibrosis - therapeutic strategies.  Digestion. 1998;  59 385-390
• 51 Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lachs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silimarin treatment in patients with cirrhosis of the liver.  J Hepatol. 1989;  9 105-113
• 52 Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis.  Int J Clin Pharmacol Ther Toxicol. 1993;  31 (9) 456-460
• 53 Calixto J B, Santos A R, Cechinel F ilho V, Yunes R A. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential.  Med Res Rev. 1998;  18 (4) 225-258
• 54 Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review.  J Viral Hepat. 2001;  8 (5) 358-366
• 55 Liu J, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B: a systematic review.  Liver. 2001;  21 (4) 280-286
• 56 Thamlikitkul V, Wasuwat S, Kanchanapee P. Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers.  J Med Assoc Thai. 1991;  74 (9) 381-385
• 57 Liu J P, McIntosh H, Lin H. Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection (Cochrane Review).  Cochrane Database Syst Rev. 2001;  2 CD002231
• 58 Liu J P, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B (Cochrane Review).  Cochrane Database Syst Rev. 2001;  1 CD001940
• 59 Flisiak R, Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B.  Hepatogastroenterology. 1997;  44 (17) 1419-1425
• 60 Flisiak R, Prokopowicz D. Effect of misoprostol on serum beta2-microglobulin in the course of viral hepatitis B.  Eur J Gastroenterol Hepatol. 1999;  11 (11) 1227-1230
• 61 Floreani A, Lobello S, Brunetto M, Aneloni V, Chiaramonte M. Colchicine in chronic hepatitis B: a pilot study.  Aliment Pharmacol Ther. 1998;  12 (7) 653-656
• 62 Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease.  Acta Physiol Hung. 1992;  80 (1-4) 363-367
• 63 Fabbri C, Mazzella G, Marchetto S, Pezzoli A. Efficacy of Ursodeoxycholic acid administration as adjuvant therapy together with alfa-interferon for chronic hepatitis C.  J Hepatology. 1997;  26 (Suppl 1) A179
• 64 Tsubota A, Kumada H, Arase Y. et al . Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.  Eur J Gastroenterol Hepatol. 1999;  11 (10) 1077-1083
• 65 Pittschieler K. Oxidative radicals and liver involvement of infants with alpha-1-antitrypsin deficiency.  Padiatr Padol. 1991;  26 (5) 235-237
• 66 Liu J P, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection (Cochrane Review).  Cochrane Database Syst Rev. 2001;  4 CD003183